Your browser doesn't support javascript.
loading
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio, Enrique M; Perrot, Aurore; Bories, Pierre; San-Miguel, Jesus F; Blau, Igor W; Karlin, Lionel; Martinez-Lopez, Joaquin; Wang, Song-Yau; Bringhen, Sara; Marcatti, Magda; Mateos, María-Victoria; Rodriguez-Otero, Paula; Oliva, Stefania; Nogai, Axel; Le Roux, Nadia; Dong, Liyan; Macé, Sandrine; Gassiot, Matthieu; Fitzmaurice, Thomas; Oprea, Corina; Moreau, Philippe.
Afiliação
  • Ocio EM; University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain. ocioem@unican.es.
  • Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.
  • Bories P; Toulouse University Institute of Cancer-Oncopole, Toulouse, France.
  • San-Miguel JF; Clinica Universidad de Navarra, CCUN, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
  • Blau IW; Charité Medical University, Berlin, Germany.
  • Karlin L; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Martinez-Lopez J; Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain.
  • Wang SY; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany.
  • Bringhen S; SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Marcatti M; Vita-Salute San Raffaele University, Milan, Italy.
  • Mateos MV; University Hospital of Salamanca, IBSAL, CSIC/CIC, Salamanca, Spain.
  • Rodriguez-Otero P; Clinica Universidad de Navarra, CCUN, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
  • Oliva S; Dipartimento di Oncologia ed Ematologia SC Ematologia 1 U, Torino, Italy.
  • Nogai A; Charité Medical University, Berlin, Germany.
  • Le Roux N; Sanofi Research & Development on behalf of Altran, Vitry-sur-Seine, France.
  • Dong L; Sanofi, Beijing, China.
  • Macé S; Sanofi Translational Medicine, Chilly-Mazarin, France.
  • Gassiot M; Sanofi Research & Development on behalf of Excelya, Montpellier, France.
  • Fitzmaurice T; Sanofi, Cambridge, MA, USA.
  • Oprea C; Sanofi Oncology, Vitry-sur-Seine, France.
  • Moreau P; University of Nantes, Nantes, France.
Leukemia ; 37(7): 1521-1529, 2023 07.
Article em En | MEDLINE | ID: mdl-37316728
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article